Reid Laurence

SEC Form 4 insider trading activity

Reid Laurence has filed 1 SEC Form 4 filing (2 transaction rows) across 1 company, with disclosures dating back to 2026. 1 of those filings fall inside the rolling window. Most recent filing: Sep 11, 2026.

On the most recent filing, Reid Laurence is listed as Director at Metagenomi Therapeutics, Inc. Inside the rolling window, Reid Laurence reported 1 open-market purchase totaling $23K in MGX and no open-market sales.

Companies traded

Other insiders at MGX

Insider Buying

$23K

reported purchases (SEC code P)

Insider Selling

$0

reported sales (SEC code S)

Companies

1

in the rolling window

Source
MGX
Reid Laurence
Purchase$23KSep 11SEC ↗
Showing 1–1 of 1
1 / 1

Frequently asked questions

How many SEC Form 4 filings has Reid Laurence made?

Reid Laurence has filed 1 SEC Form 4 filing (2 transaction rows) across 1 company since 2026.

Which companies does Reid Laurence trade?

Reid Laurence has filed SEC Form 4 disclosures for 1 company, including MGX.

When was Reid Laurence's most recent SEC Form 4 filing?

Reid Laurence's most recent SEC Form 4 filing on Tracefour is dated Sep 11, 2026.

What is Reid Laurence's total buy and sell value in the current window?

Inside the rolling retention window, Reid Laurence bought $23K and sold $0 based on SEC Form 4 filings.

What was Reid Laurence's largest disclosed transaction?

The largest disclosed transaction in the current window is a purchase of 20,000 MGX shares on 2026-09-09, worth $23K, per SEC Form 4 filings.